Marksans Pharma Limited
Σύμβολο: MARKSANS.NS
NSE
158.25
INRΤιμή αγοράς σήμερα
22.7836
Λόγος P/E
0.5408
Δείκτης PEG
71.71B
MRK Cap
- 0.00%
DIV Απόδοση
Marksans Pharma Limited (MARKSANS-NS) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 27678.4 | 7191.6 | 3466.9 | 2093.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 34038.7 | 3367.2 | 4.3 | 17.2 | |||||||||||||||||||
balance-sheet.row.net-receivables | 8696.08 | 4187.6 | 4115.6 | 2767.3 | |||||||||||||||||||
balance-sheet.row.inventory | 10153.42 | 4847.4 | 4244.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 1029.74 | 526.4 | 185.1 | 118.2 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 47557.64 | 16753 | 12012 | 9022.5 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 8581.34 | 3868.9 | 3422.9 | 2540.2 | |||||||||||||||||||
balance-sheet.row.goodwill | 771.91 | 384.9 | 300.3 | 195.9 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1395.4 | 708 | 585.7 | 474.4 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2167.31 | 1092.9 | 885.9 | 670.2 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -6433 | -3332.4 | -62 | 8.4 | |||||||||||||||||||
balance-sheet.row.tax-assets | 6517.3 | 3375.9 | 38.6 | 8 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | -13350.95 | 145.7 | 103.7 | 33.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | -2518 | 5150.9 | 4389 | 3260 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 45039.64 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.account-payables | 4309.35 | 2306 | 2000.8 | 1686.6 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 1073.1 | 572.6 | 693.4 | 247.8 | |||||||||||||||||||
balance-sheet.row.tax-payables | 667.33 | 252.8 | 173.3 | 300.2 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1267.38 | 656.9 | 414.3 | 93.3 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 121.1 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 321.13 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 376.6 | 112.4 | 543 | 639.3 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1681.51 | 843.3 | 609.1 | 245 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 1572.51 | 813.6 | 694.9 | 153.6 | |||||||||||||||||||
balance-sheet.row.total-liab | 8418.8 | 4253.2 | 4171.3 | 3229 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 13274.17 | 13274.2 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 906.32 | 453.2 | 409.3 | 409.3 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 10913.4 | 10913.4 | 5093.1 | 3349.3 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 58687.73 | 4177.4 | 4788.4 | 3355 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | -10953.25 | -11366.6 | 1731.9 | 1751.3 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 72828.37 | 17451.6 | 12022.7 | 8864.9 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 81660.48 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.minority-interest | 413.31 | 199.1 | 207 | 188.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 73241.68 | 17650.7 | 12229.7 | 9053.5 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 81660.48 | - | - | - | |||||||||||||||||||
Total Investments | 27605.7 | 34.8 | 26.1 | 25.6 | |||||||||||||||||||
balance-sheet.row.total-debt | 2340.48 | 1229.5 | 1107.8 | 341 | |||||||||||||||||||
balance-sheet.row.net-debt | 8700.78 | -2594.9 | -2354.8 | -1752.8 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3181.21 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1114.7 | -1107 | -1500.3 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | -275.2 | -1039.3 | -367.4 | |||||||||||||||||
cash-flows.row.inventory | 0 | -448.5 | -178.5 | -1624.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 224.2 | 184.9 | 417.8 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -615.2 | -74.1 | 74.1 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -3181.21 | -406.3 | -823.3 | -95.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1343.16 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -266.1 | 0.3 | 5.2 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -1897.7 | -1.5 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2163.8 | -0.3 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | -2055.8 | 47.9 | 10.1 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2592.1 | -416.9 | -449 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2295.4 | -225.5 | -1 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 2747.1 | 911.5 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -451.7 | -225.5 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -101.7 | -105.8 | -40.9 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2080 | 440.4 | -110.9 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1978.3 | 795.1 | -152.9 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -1428.6 | -1 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 1343.16 | 1760.3 | 1370.8 | 1185.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 21580.94 | 3824.4 | 3492.7 | 2122.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 20237.78 | 2064.1 | 2121.8 | 937.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 1343.16 | 2374.1 | 992.6 | 1787.4 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.free-cash-flow | 1343.16 | 1837.8 | 529.3 | 1323.2 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 21033.72 | 18521.4 | 14801.2 | 13683.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 10121.39 | 9213.6 | 7480.2 | 6186 | |||||||||||||||||||
income-statement-row.row.gross-profit | 10912.33 | 9307.8 | 7321.1 | 7497.8 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 283.89 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 6999.05 | 6433.1 | 5153.7 | 4310.6 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 17120.44 | 15646.7 | 12633.9 | 10496.6 | |||||||||||||||||||
income-statement-row.row.interest-income | 158.31 | 59.4 | 59.7 | 11.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 5033.87 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 4261.33 | 2877.3 | 2141 | 3092.2 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 4274.26 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 1074.63 | 723.3 | 607 | 636.3 | |||||||||||||||||||
income-statement-row.row.net-income | 3173.43 | 2663.1 | 1845.7 | 2385.4 |
Συχνές ερωτήσεις
Ποιο είναι το Marksans Pharma Limited (MARKSANS.NS) το σύνολο του ενεργητικού?
Marksans Pharma Limited (MARKSANS.NS) το συνολικό ενεργητικό είναι 21903890000.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι 11173630000.000.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.519.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι 2.964.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι 0.151.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι 0.203.
Ποια είναι η Marksans Pharma Limited (MARKSANS.NS) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι 2663080000.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 1229450000.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 6433130000.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι -6611350000.000.